On May 31, 2023, clinical-stage company Seal Rock Therapeutics announced an out-licensing agreement with biopharmaceutical company GENFIT to develop an injectable formulation of SRT-015 to treat acute liver disease. Wilson Sonsini Goodrich & Rosati advised Seal Rock on the transaction.

Seattle-based Seal Rock is a privately held company that focuses on developing treatments for severe diseases with limited or no available therapies. SRT-015 is a second-generation liver-selective inhibitor that will be available in an oral formulation to treat severe acute alcoholic hepatitis as well as orphan liver diseases.

As part of the agreement, Seal Rock is eligible to receive up to €100 million, which includes regulatory, clinical, and commercial milestone payments, plus tiered royalties.

Wilson Sonsini's team advising Seal Rock includes Miranda Biven, Sai Upadhyayula, Ingo Hardt, Jim Malecha, and Christina Hoong.

For more information, please see the press release.